Related Experiment Videos

The 2000 United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) inhibitor guidelines

C R M Hay1,

  • 1Manchester Thrombosis and Haemostasis Centre, Manchester, UK. haemophilia@man.ac.uk

Pathophysiology of Haemostasis and Thrombosis
|September 6, 2002
PubMed

Insights

The UKHCDO inhibitor guidelines offer best practices for managing haemophilia A, B, and acquired haemophilia. Evidence highlights the need for more controlled studies to refine treatment strategies for inhibitors.

Area of Science:

  • Hematology
  • Clinical Guidelines
  • Evidence-Based Medicine

Background:

  • Guidelines address diagnosis and management of haemophilia A, haemophilia B, and acquired haemophilia.
  • Recommendations are derived from the current evidence base and best practices.
  • Existing treatment strategies often rely on uncontrolled observations.

Framework:

  • The UKHCDO inhibitor guidelines provide a framework for clinical decision-making.
  • Focuses on the diagnosis and management of inhibitors in haemophilia patients.
  • Emphasizes the integration of current evidence into practice.

Implementation:

  • Guidelines offer practical recommendations for healthcare providers.
  • Aims to standardize the care of patients with haemophilia and inhibitors.
  • Highlights areas where current practice may need enhancement.

Implications:

  • Current treatment strategies require further validation through controlled studies.
  • The guidelines underscore the need for rigorous research to advance patient care.
  • Improved evidence base will lead to more effective management of haemophilia inhibitors.

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...